Liposomes containing monophosphoryl lipid A: a potent adjuvant system for inducing antibodies to heroin hapten analogs

Vaccine. 2013 Jun 10;31(26):2804-10. doi: 10.1016/j.vaccine.2013.04.027. Epub 2013 Apr 23.

Abstract

In order to create an effective immunization approach for a potential vaccine to heroin, liposomes containing monophosphoryl lipid A [L(MPLA)] were tested as an adjuvant system to induce antibodies to heroin hapten analogs. Four synthetic haptens and two immunization strategies were employed. In the first strategy, a hydrophobic 23 amino acid immunogenic peptide derived from the membrane proximal external region of gp41 from HIV-1 envelope protein was embedded as a carrier in the outer surface of L(MPLA), to which was conjugated a 15 amino acid universal T cell epitope and a terminal heroin hapten analog. In the second strategy, tetanus toxoid (TT) carrier protein was decorated with haptens by conjugation, and the hapten-conjugated protein was mixed with L(MPLA). After immunization of mice, each of the immunization strategies was effective for induction of IgG anti-hapten antibodies. The first immunization strategy induced a mean end-point IgG titer against one of two haptens tested of approximately 12,800; however, no detectable antibodies were induced against the liposome-associated HIV-1 carrier peptide. In the second immunization strategy, depending on the hapten used for decorating the TT, end-point IgG titers ranged from 100,000 to 6,500,000. In this strategy, in which hapten was conjugated to the TT, end-point IgG titers of 400,000 to the TT carrier were observed with each conjugate. However, upon mixing unconjugated TT with L(MPLA), anti-TT titers of 6,500,000 were observed. We conclude that L(MPLA) serves as a potent adjuvant for inducing antibodies to candidate heroin haptens. However, antibodies to the carrier peptide or protein were partly or completed inhibited by the presence of conjugated hapten.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, N.I.H., Intramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Adjuvants, Immunologic* / administration & dosage
  • Adjuvants, Immunologic* / chemistry
  • Animals
  • Antibody Formation
  • Epitopes, T-Lymphocyte / chemistry
  • Epitopes, T-Lymphocyte / immunology
  • Feasibility Studies
  • Female
  • HIV Envelope Protein gp41 / chemistry
  • HIV Envelope Protein gp41 / immunology
  • Haptens / chemistry
  • Haptens / immunology*
  • Heroin / immunology*
  • Lipid A / administration & dosage
  • Lipid A / analogs & derivatives*
  • Lipid A / chemistry
  • Lipid A / immunology
  • Liposomes*
  • Mice
  • Mice, Inbred BALB C
  • Opioid-Related Disorders / immunology
  • Opioid-Related Disorders / prevention & control
  • Peptides / chemistry
  • Peptides / immunology
  • Tetanus Toxoid / chemistry
  • Tetanus Toxoid / immunology
  • Vaccines / immunology

Substances

  • Adjuvants, Immunologic
  • Epitopes, T-Lymphocyte
  • HIV Envelope Protein gp41
  • Haptens
  • Lipid A
  • Liposomes
  • Peptides
  • Tetanus Toxoid
  • Vaccines
  • Heroin
  • monophosphoryl lipid A